Additional file 1 of Lysophosphatidic acid species are associated with exacerbation in chronic obstructive pulmonary disease
Creators: name: Li, Qingling
name: Wong, Weng
name: Birnberg, Andrew
name: Chakrabarti, Arindam
name: Yang, Xiaoying
name: Choy, David F.
name: Olsson, Julie
name: Verschueren, Erik
name: Neighbors, Margaret
name: Sandoval, Wendy
name: Rosenberger, Carrie M.
name: Grimbaldeston, Michele A.
name: Tew, Gaik W.
Publisher: name: figshare
Year: 2021
Subjects: subject: Medicine
subject: Cell Biology
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Science Policy

description: Additional file 1. Table S1. Patient baseline characteristics by LPA18:0 subgroups. Table S2. Patient baseline characteristics by LPA18:1 subgroups. Table S3. Patient baseline characteristics by LPA18:2 subgroups. Table S4. Patient baseline characteristics by LPA20:4 subgroups. Table S5. List of investigator and Institutional Review Board / Ethics Committee approval. Figure S1. Baseline serum LPA levels by (A) sex, (B) smoking status, and (C) COPD medications; double = ICS with one bronchodilator; triple = ICS with two bronchodilators. Median and interquartile range shown as boxplot. M, male; F, female. **p &lt; 0.005; *** p &lt; 0.001; ns, not significant, Student t-test on log2 transformed LPA. Figure S2. Differences in exacerbation duration among LPA subgroups. Median and interquartile range shown as boxplot. L = lowest-; M = medium-; H = highest-tertile of the respective LPA levels; N, number of exacerbation events. Kruskal-Wallis p-values shown. Figure S3. Baseline serum LPA levels and time since last exacerbation before study entry. P-values showed the association of LPA with time since last exacerbation before patients were enrolled into the study in a multivariate regression adjusted for the following covariates: number of exacerbations within the last 12 months, smoking status, geographical region, baseline COPD medications, and sex. P = ns, not significant; uM, microMolar. Figure S4. Differential lipid expression by baseline biomarker profile. (A) Profiling of 12 classes of lipids in LPA low versus high patients. The x axis denotes the average log2 (analyte abundance in low/analyte abundance in high); values less than 0 indicate a decrease, and values greater than 0 an increase, in low versus high patients. Green bars denote unadjusted p-value &lt; 0.05; orange bars denote false discovery rate &lt; 0.05. CE, cholesteryl esters; CER, ceramides; DAG, diacylglycerols; DCER, dihydroceramides; HCER, hexosylceramides; LCER, lactosylceramides; LPC, lysophosphatidylcholines; LPE, lysophosphatidylethanolamines; PC, phosphatidylcholines; PE, phosphatidylethanolamines; SM, sphingomyelins; TAG, triacylglycerols. (B) Volcano plots showing lipid species in LPA low versus high patients. The x axis denotes log2(analyte abundance in low/analyte abundance in high), and the y axis indicates the -log10(unadjusted p-value). Colored circles denote unadjusted p-value&lt;0.05; red circles denote lipid species with higher abundance in LPA-low compared to LPA-high (fold change &gt; 0.5); blue circles denote lipid species with lower abundance in LPA-low compared to LPA-high (fold change &gt; 0.5).